GSK inks licensing deal worth up to $1B with China's Frontier Bio
Source: SeekingAlpha
2026-02-24 08:51:38 ET
More on GSK
- GSK: Post-Pivot Buoyancy Set To Continue After Strong 2025 (Upgrade)
- GSK plc 2025 Q4 - Results - Earnings Call Presentation
- GSK plc (GSK) Q4 2025 Earnings Call Transcript
- CDC said to delay vaccine panel meeting after lawsuit challenging its composition
- GSK says RSV shot Arexvy lowers risk of CV events, asthma, and COPD
Read the full article on Seeking Alpha
For further details see:
GSK inks licensing deal worth up to $1B with China’s Frontier Bio
Arrowhead Pharmaceuticals Inc.
NASDAQ: ARWR
ARWR Trading
-2.77% G/L:
$57.94 Last:
887,156 Volume:
$58.89 Open:
ARWR Latest News
February 24, 2026 07:30:00 am
Arrowhead Pharmaceuticals to Participate in Upcoming March 2026 Events
February 17, 2026 09:05:00 am
Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A
ARWR Stock Data
$8,824,478,533
134,991,031
3.4%
157
N/A
Biotechnology & Life Sciences
Healthcare
US
Pasadena
